Clinical Report: New Alzheimer's Disease Criteria Released
Overview
The Alzheimer's Association has released revised criteria for the diagnosis and staging of Alzheimer's disease, published in 2024. These criteria emphasize a biological definition based on biomarkers and outline a continuum of the disease, integrating biological and clinical stages.
Background
Accurate diagnosis and staging of Alzheimer's disease (AD) are crucial for effective management and treatment. The shift towards a biological definition reflects advancements in understanding the disease's pathology. The incorporation of biomarkers into diagnostic criteria represents a significant evolution in the clinical approach to AD.
Data Highlights
The revised criteria categorize biomarkers into Core 1 and Core 2. Core 1 biomarkers, such as amyloid PET and cerebrospinal fluid biomarkers, are sufficient for diagnosis. Core 2 biomarkers provide prognostic information and confirm AD's contribution to symptoms.
Key Findings
- The revised criteria emphasize a biological definition of Alzheimer's disease based on biomarkers.
- AD is now viewed as a continuum starting with asymptomatic brain changes.
- Core 1 biomarkers are sufficient for diagnosis.
- Core 2 biomarkers provide prognostic information.
- The criteria do not support evaluating asymptomatic individuals for clinical care outside research.
- Comorbid pathologies should be identified as they may influence prognosis and treatment decisions.
Clinical Implications
The integration of biomarkers into clinical practice may improve diagnostic accuracy.
Conclusion
The revised criteria for Alzheimer's disease diagnosis and staging emphasize the role of biomarkers in clinical practice.
Related Resources & Content
- Alzheimer's Association Workgroup Publishes Biology-Based Criteria for Diagnosis and Staging of Alzheimer's Disease, Alzheimer's Association, 2024 -- Revised Alzheimer's Diagnostic Criteria
- Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup, Alzheimer's & Dementia, 2025 -- Appropriate Use Criteria for PET
- Brain — Opposing views or like-minded? International Working Group and Alzheimer’s Association criteria
- Acta Neuropathologica — Exploring the Impact of Amyloid-β on the Definition, Etiology, and Diagnosis of Alzheimer’s Disease
- Acta Neuropathologica — Criteria for Neuropathological Diagnosis of Progressive Supranuclear Palsy Established by the Rainwater Charitable Foundation
- Acta Neuropathologica — Plasma Biomarkers Associated with Alzheimer’s Disease: Links to Neuropathological Changes and Cognitive Decline
- Alzheimer's Association Workgroup Publishes Biology-Based Criteria for Diagnosis and Staging of Alzheimer's Disease
- Updated appropriate use criteria for amyloid and tau PET
- FDA Roundup: July 2, 2024 | FDA
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
